Bifidobacterium animalis: A Comprehensive Reference
1. Identity: Nomenclature, Taxonomy, and Natural Sources
1.1 Scientific Classification and Nomenclature
Bifidobacterium animalis was first described by Mitsuoka in 1969 and formally named Bifidobacterium animalis (Mitsuoka 1969) Scardovi and Trovatelli 1974. Its full taxonomic lineage runs: cellular organisms → Bacteria → Bacillati → Actinomycetota → Actinomycetes → Bifidobacteriales → Bifidobacteriaceae → Bifidobacterium.
Bifidobacterium animalis and Bifidobacterium lactis were previously described as two distinct species. Presently, both are considered B. animalis, comprising two subspecies: Bifidobacterium animalis subsp. animalis and Bifidobacterium animalis subsp. lactis. Both old names B. animalis and B. lactis are still used on product labels, as this species is frequently used as a probiotic. In most cases, which subspecies is used in the product is not clear.
The levels of DNA–DNA hybridization between the type strains of Bifidobacterium animalis and Bifidobacterium lactis range from 85.5 to 92.3%, and Bifidobacterium animalis (Mitsuoka 1969) Scardovi and Trovatelli 1974 is recognized as an earlier heterotypic synonym of Bifidobacterium lactis Meile et al. The formal reclassification was published in 2004, when polyphasic taxonomic analysis confirmed that B. animalis and B. lactis were related at the subspecies level.
Bifidobacterium is a genus of lactic-acid-producing, Gram-positive, non-spore-forming, non-motile, anaerobic bacteria. Bifidobacteria were first discovered and isolated from the feces of a breast-fed infant in 1899, and they are common constituents of the indigenous microbiota in the human intestinal tract.
1.2 Notable Commercially Used Strains
The subspecies B. animalis subsp. lactis encompasses the most commercially studied strains. Common commercial strains include BB-12®, HN019, CNCM I-3446 (BI-07), BL-04, and B420, with strain designations varying by manufacturer.
The probiotic strain Bifidobacterium animalis subsp. lactis BB-12® is described as the world's most documented probiotic Bifidobacterium, appearing in more than 300 scientific publications, of which more than 130 are publications of human clinical studies.
BB-12® is a catalase-negative, rod-shaped bacterium. It was deposited in the cell culture bank of Chr. Hansen in 1983. At the time of isolation, BB-12® was considered to belong to the species Bifidobacterium bifidum. Modern molecular classification techniques reclassified BB-12® as Bifidobacterium animalis and later to a new species Bifidobacterium lactis. The species B. lactis was later shown not to fulfill the criteria for a species and was instead included in Bifidobacterium animalis as a subspecies. Today, BB-12® is therefore classified as Bifidobacterium animalis subsp. lactis.
Strain HN019 (also known as DR10) is a strain from Fonterra that is licensed to DuPont, which markets it as HOWARU Bifido. Danone (Dannon in the United States) markets the subspecies strain DN 173 010 under various brand names depending on the country.
1.3 Natural Habitat and Sources
Bifidobacterial species have been used in fermented dairy products traditionally. Bifidobacterium animalis subsp. lactis is notably found as a food product isolate. B. animalis subsp. lactis DSM 10140 (originally identified as B. lactis) was first described in 1997 as a unique species of Bifidobacterium and was identified as an oxygen-tolerant isolate from a fermented milk sample.
Bifidobacteria are primarily found in the gastrointestinal tracts of mammals, with certain strains being host-specific. In humans, they are most abundant in infants, particularly those who are breastfed, due to their ability to digest human milk oligosaccharides. They are naturally present in healthy adults' colon and large intestine, though in lower abundance than in infants.
2. Traditional and Historical Use
Bifidobacteria as a group have no traditional medicinal use in the way single plants or herbs do. They have long been recognized as typical constituents of healthy infant and adult gut microbiota; traditional use is essentially dietary consumption of fermented dairy products containing live bifidobacteria.
Bifidobacteria have a long history of safe consumption in fermented milk products. They were historically used via yogurt and cultured milk products to promote digestive comfort and preservation. Bifidobacterial species have been used in fermented dairy products traditionally, and certain strains are "Generally Recognized As Safe."
B. animalis subsp. lactis's modern applications are as strain-banked probiotic ingredients in capsules, powders, and infant formula with documented safety data for certain strains. The deliberate, standardized industrial use of specific, genetically characterized strains of B. animalis in probiotic products is a distinctly modern practice beginning in the latter decades of the 20th century, supported by formal clinical evaluation from the late 1980s onward.
Dating back to 1987, BB-12® has been tested in clinical trials for more than 25 years.
3. Key Constituents, Genomic Characteristics, and Mechanisms of Action
3.1 Genomic Architecture
The BB-12 genome consists of a single circular chromosome of 1,942,198 base pairs with 1,642 predicted protein-encoding genes, 4 rRNA operons, and 52 tRNA genes. The complete genome sequence of BB-12® has been determined and published.
Analyses of previously sequenced genomes of B. animalis subsp. lactis have revealed little genetic diversity, suggesting that it is a monomorphic subspecies. Genome annotation using COG analysis across multiple strains reveals a conserved set of core functional protein categories, with amino acid transport and metabolism, translation, ribosomal structure and biogenesis, carbohydrate transport and metabolism, and transcription being the most abundant.
3.2 Physiological Characteristics and Probiotic Traits
BB-12® exhibits excellent gastric acid and bile tolerance; it contains bile salt hydrolase, and has strong mucus adherence properties, all valuable probiotic characteristics. Pathogen inhibition, barrier function enhancement, and immune interactions are mechanisms that all have been demonstrated for BB-12®.
BB-12 is technologically well suited, expressing fermentation activity, high aerotolerance, good stability, and a high acid and bile tolerance. Because of the high redox potential in the colon flora ecosystem, BB-12 is highly resistant against acidic pH, digestive enzymes, and the toxic effect of bile acids.
Bifidobacterium animalis shows remarkable acid tolerance and distinct species-specific characteristics. The survival rate of strains from B. animalis evaluated under pH 2.5 for 2 hours shows that all B. animalis strains maintained survival rates above 60%, whereas other Bifidobacterium species fell below the detection limit.
B. animalis subsp. lactis is the most common Bifidobacterium species included in fermented dairy products, due to its good tolerance to both acidic and oxidative stress, being able to maintain higher viability during product storage than other species.
3.3 Key Mechanisms of Action
Short-Chain Fatty Acid (SCFA) Production and Receptor Signaling: Short-chain fatty acids (SCFAs), which are metabolites derived from the fermentation of dietary fiber by the gut microbiota, are important for host metabolic health. There is interest in probiotics for their beneficial effects on metabolic disorders, such as obesity, but the underlying mechanisms remain largely unknown. Strain GCL2505, a probiotic capable of proliferating and increasing SCFA levels in the gut, exerts anti-metabolic syndrome effects via the SCFA receptor G protein-coupled receptor 43 (GPR43). GCL2505 treatment suppressed body fat accumulation, improved glucose tolerance, and enhanced systemic fatty acid oxidation in high-fat-diet-fed wild-type mice, whereas these effects were not observed in Gpr43 knockout mice.
Gut–Brain Axis and Motility Signaling: B. lactis HN019™ reduced intestinal transit time and increased bowel movement frequency in functional constipation, potentially by modulating the gut–brain–microbiota axis, mainly via the serotonin signaling pathway, through short-chain fatty acids derived from microbial fermentation. B. lactis HN019™ is thus a probiotic that can contribute to relieving gut dysmotility-related disorders.
Intestinal Barrier and Pathogen Exclusion: Research supports the hypothesis that B. lactis HN019™ has a beneficial role in maintaining intestinal barrier function during gastrointestinal infections by competing and excluding potential pathogens via different mechanisms, maintaining normal tight junction function in vitro, and regulating host immune defense toward pathogens in both in vitro and human studies. This has been observed to lead to reduced incidence of diarrhea. B. lactis HN019™ also supports normal physiological function in immunosenescent elderly and competes and excludes potential pathogens.
Immune Modulation: Evidence suggests that Bifidobacteria supplementation, which serves to restore a balanced microbial composition, modulates immune function, gut microbiota, and intestinal mucosal adhesion in IBS patients, with studies demonstrating positive effects on epithelial cell adherence, reinforcement of tight junctions, stimulation of IgA production, and cell-mediated immunity.
Microbial Ecosystem Modulation: High-throughput sequencing of the 16S rRNA shows that B. lactis supplementation can reverse high-fat-diet-induced gut microbiota dysbiosis, related to augmented abundance of SCFA-producing bacteria and a minimized ratio of Bacteroidetes to Firmicutes in animal models.
Adhesion Properties: Bifidobacterium animalis subsp. lactis JCM 10602 demonstrated a great adhesion potential to dietary fibers present in the intestinal tract, which may further affect adhesion to intestinal epithelial cells. The adhesion mechanism primarily involved hydrophobic and electrostatic interactions in the case of cellulose and chitin, respectively.
4. Scientific Evidence by Area of Use
4.1 Gastrointestinal Health: Constipation and Bowel Function
This is the most extensively studied area for B. animalis subsp. lactis. Multiple strains have been evaluated, with the most clinical data available for BB-12® and HN019.
BB-12® and Bowel Function: Clinical studies have demonstrated survival of BB-12® through the gastrointestinal tract, and BB-12® has been shown to support a healthy gastrointestinal microbiota. Furthermore, BB-12® has been shown to improve bowel function, to have a protective effect against diarrhea, and to reduce side effects of antibiotic treatment, such as antibiotic-associated diarrhea.
HN019 Dose-Ranging Trial (Ibarra et al., 2018, Gut Microbes): The aim of one rigorous dose-ranging study was to determine the efficacy and safety of 28-day supplementation with 1 × 10⁹ or 1 × 10¹⁰ CFU of HN019/day for constipation. A total of 228 adults who were diagnosed with functional constipation according to the Rome III criteria were randomized in a double-blind and placebo-controlled trial. Colonic transit time (CTT), the primary outcome, and secondary outcomes that included stool consistency, bowel movement frequency, degree of straining, bowel emptying, bloating, and pain severity were assessed. There were no statistically significant differences in the primary or secondary outcomes between interventions. The trial was preceded by a 14-day run-in period, was registered at ClinicalTrials.gov, and was conducted in full compliance with GCP standards. This negative result for the primary endpoint is important context for the overall evidence base.
Synbiotic Approaches: The combined administration of prebiotics and probiotics in synbiotic formulations augments effects, particularly in fostering the production of short-chain fatty acids, essential for mucosal health and intestinal motility regulation. Specific formulations, including fructooligosaccharides (FOS) and galactooligosaccharides (GOS) paired with Bifidobacterium strains, have demonstrated significant reductions in gut transit time, increased stool frequency, and improved consistency.
Overall strength of evidence for constipation: Moderate, with mixed results. Several positive studies exist for BB-12®, but a well-powered dose-ranging RCT for HN019 did not meet its primary endpoint. Evidence for improvement in bowel movement frequency with specific strains is generally stronger than evidence for changes in measured colonic transit time.
4.2 Gastrointestinal Health: Irritable Bowel Syndrome (IBS)
Agrawal and colleagues investigated Bifidobacterium lactis in a fermented milk product consumed daily over a 4-week intervention compared to a daily probiotic-naïve placebo non-fermented product. Individuals under the treatment condition were found to have significantly lower levels of abdominal pain compared to the control group.
An RCT investigated fermented milk containing Bifidobacterium animalis DN-173 010 on health-related quality of life and symptoms in IBS in adults in primary care, and a separate clinical trial studied the effects of a fermented milk product containing Bifidobacterium lactis DN-173010 on abdominal distension and gastrointestinal transit in IBS with constipation.
Three clinical trials and a simple review have demonstrated improvement in IBS symptoms, although further studies are needed. Guidelines and systematic reviews have not demonstrated superiority of Bifidobacterium in symptomatic relief when compared to other probiotic species. A meta-analysis did not show the efficacy of the isolated use of Bifidobacterium. The evidence of an association between Bifidobacterium supplementation and symptomatic control in patients with IBS is not clear. Some studies seem to demonstrate benefits in improving symptoms (SORT C evidence level).
Overall strength of evidence for IBS: Preliminary and mixed. Individual RCTs show modest positive signals, but systematic reviews and meta-analyses do not support a definitive, species-level efficacy claim. Evidence is stronger for IBS-C (constipation-predominant) subtypes with certain fermented dairy preparations.
4.3 Antibiotic-Associated Diarrhea
The administration of broad-spectrum antibiotics is often associated with antibiotic-associated diarrhea (AAD), and impacts gastrointestinal tract homeostasis, including an overall reduction in the numbers and diversity of the gut microbiota and decreased short-chain fatty acid production. Evidence in humans that probiotics may enhance the recovery of microbiota populations after antibiotic treatment is equivocal.
One randomized, allocation-concealed, controlled trial studied whether Bifidobacterium animalis subsp. lactis BB-12-containing yogurt could protect against antibiotic-induced fecal SCFA and microbiota composition disruptions. The trial assessed amoxicillin/clavulanate administration (days 1–7), in conjunction with either BB-12-containing or control yogurt (days 1–14).
BB-12-supplemented yogurt was found to be safe and well tolerated when consumed by healthy adults concurrently taking antibiotics. This study was framed as the basis for future randomized clinical trials investigating the potential immunomodulatory effects of BB-12-supplemented yogurt in a variety of disease states.
Overall strength of evidence for AAD: Moderate for safety and tolerability; evidence for efficacy in preventing or reducing AAD duration specifically is suggestive but not conclusively established in high-quality independent trials for this organism specifically.
4.4 Immunity and Upper Respiratory Tract Infections (URTI)
In terms of immune function, clinical studies have shown that BB-12® increases the body's resistance to common respiratory infections as well as reduces the incidence of acute respiratory tract infections.
NK and T-cell study (Meng et al., 2016): In a randomized, partially blinded, four-period crossover study, healthy adults (n = 30) were recruited and received four treatments for 4 weeks in random order, including yogurt smoothies alone, smoothies with BB-12 added before or after yogurt fermentation, or a BB-12 capsule. NK- and T-cell function was assessed at baseline and after each treatment, and incidence and severity of cold/flu infection was quantified using self-reported URTI questionnaires. Participants on yogurt smoothies alone, BB-12 pre-fermentation, or capsule treatments had elevated IL-2 secretion and NK-cell cytotoxicity, concurrently with fewer days with URTI. However, the post-fermentation treatment did not change immune outcomes or the severity of URTI. The timing of BB-12 addition to yogurt smoothies in relation to the fermentation process influenced the impact of BB-12 on immune function and cold/flu severity in young healthy adults.
Pediatric RTI study (2026): Supplementation with lactoferrin combined with Bifidobacterium animalis subsp. lactis BB-12 in healthy children was associated with clinical improvement alongside concurrent alterations in gut microbial structure and functional profiles, suggesting that this combined intervention may contribute to the maintenance of host immune homeostasis through modulation of the gut microbiome. In this study, the combined intervention was associated with attenuation of symptoms and a reduced disease burden among children with RTIs, rather than a significant reduction in RTI incidence.
Overall strength of evidence for immunity/URTI: Moderate but limited. Multiple small human studies demonstrate favorable effects on immune cell function and reduction in URTI duration/severity. However, study sizes are generally small, and effects can depend on delivery format (e.g., timing of addition to fermented foods) and the presence of co-interventions (e.g., lactoferrin). Independent replication in large RCTs is needed.
4.5 Lactose Digestion
Bi-07 crossover clinical trials (Am J Clin Nutr, 2022): Two crossover clinical trials (Booster Alpha and Booster Omega) were performed in participants with lactose intolerance, where 2 × 10¹² CFUs of Bi-07, 4662 FCC lactase, or placebo was consumed simultaneously with a lactose challenge, with 1-week washouts between challenges. Breath hydrogen concentration (BHC) was measured to assess the effect on lactose digestion, for which incremental area under the curve (iAUC) was the primary outcome; peak BHC, cumulative BHC, and GI symptoms were secondary outcomes. Bi-07 was superior to placebo in reducing BHC in both trials.
Overall strength of evidence for lactose digestion: Promising but very specific to the Bi-07 strain and the very high dose (2 × 10¹²) used. These findings are not automatically generalizable to other B. animalis strains or typical supplemental doses.
4.6 Metabolic Health and Body Composition
Research evaluating strain GCL2505 — a probiotic strain capable of proliferating and increasing SCFA levels in the gut — found it exerts anti-metabolic syndrome effects via the SCFA receptor GPR43. In high-fat-diet-fed wild-type mice, GCL2505 treatment suppressed body fat accumulation, improved glucose tolerance, and enhanced systemic fatty acid oxidation. These effects were not observed in GPR43 knockout mice.
The anti-obesity effects of B. lactis A12 in animal models were closely related to the assembly of SCFAs, SCFA-downstream receptors, and glucagon-like peptide-1 (GLP-1) secretion. Supplementation reversed high-fat-diet-induced gut microbiota dysbiosis, related to augmented abundance of SCFA-producing bacteria and a minimized ratio of Bacteroidetes to Firmicutes. Proposed mechanisms include downregulation of sterol regulatory element binding protein-1 mRNA levels in the liver, modulation of gut microbiota, and upregulation of the SCFA-producing bacteria-related GPR43 pathway.
Overall strength of evidence for metabolic health: Largely preclinical (animal models). The mechanistic hypotheses involving GPR43 and SCFA signaling are scientifically plausible and supported by mechanistic animal data, but robust human RCTs demonstrating meaningful changes in body composition or glycemia specifically attributable to B. animalis strains are limited. The evidence at this stage does not support a clinical claim in humans.
4.7 Infant Health: Diarrhea and Colic
B. animalis subsp. lactis BB-12® has been associated with a reduced incidence of acute diarrhea, softer and more frequent bowel movements, fewer and shorter episodes of diarrhea, and a significant reduction in excessive crying and fussing in infants with colic in cited clinical studies.
BB-12® has been used in infant formula, dietary supplements, and fermented milk products worldwide. By December 2020, there were 42 studies/clinical trials published involving HN019 in 27 investigated cohorts, including both healthy and compromised subjects in all age groups from newborns to elderly. The investigational products contain HN019 as a single strain or combined with other probiotics and/or prebiotics. The daily dosage ranged from 10⁷ to 10¹¹ colony forming units (CFU) per day, and consumption lasted from 7 days to 2 years.
Overall strength of evidence in infants: Moderate for diarrhea reduction and tolerability. The breadth of study populations is notable, but effect sizes and consistency across independent groups remain variable. Strain specificity is critical.
5. Body Systems Associated with Bifidobacterium animalis
- Gastrointestinal system: Health benefits attributed to this subspecies include modulation of the immune system, increased digestive comfort, and reduction of colonic transit time. Specific outcomes studied include constipation relief, IBS symptom management, diarrhea prevention (including antibiotic-associated), and barrier integrity.
- Immune system: BB-12 has been shown to modulate gut microbiota composition, enhance mucosal immune function, and reduce infection susceptibility. NK cell activity, IgA secretion, and T-cell function have been assessed in human trials.
- Respiratory system: Evidence to date suggests that probiotics may reduce the incidence and severity of RTIs via immunomodulatory mechanisms and reinforcement of mucosal barrier function.
- Metabolic system: Preclinical data support modulation of energy metabolism via SCFA–GPR43 signaling, though human evidence remains limited.
- Skin: BB-12® has been associated with reduced severity, extent, and subjective symptoms of atopic eczema in infants with atopic inflammation in cited clinical studies.
6. Dosage Forms and Reported Dosages
Dosage forms: B. animalis is present in many food products and dietary supplements, and the probiotic is mostly found in dairy products. BB-12® has been used in infant formula, dietary supplements, and fermented milk products worldwide. This strain is technologically well suited, expressing fermentation activity, high aerotolerance, good stability, and a high acid and bile tolerance, also as freeze-dried products in dietary supplements. Preparations include fermented milks (yogurts), capsules, powders, and infant formulas.
Ranges reported in clinical studies:
- BB-12® has been tested in clinical trials including subjects from preterm infants to elderly, and it has been administered in dosages up to 100 billion CFU/day.
- The daily dosage of HN019 in published clinical trial investigational products ranged from 10⁷ to 10¹¹ CFU per day, and consumption lasted from 7 days to 2 years.
- A key RCT in functional constipation tested 28-day supplementation with 1 × 10⁹ or 1 × 10¹⁰ CFU of HN019 per day.
- A lactose digestion trial used 2 × 10¹² CFUs of strain Bi-07, consumed simultaneously with a lactose challenge.
- FDA GRAS notices have described intended use at levels from 10⁹ to 10¹¹ CFU/serving.
B. lactis exhibits relatively greater aerotolerance versus many bifidobacteria, aiding manufacturing stability. Different strains produce distinct clinical outcomes — strain identity (e.g., BB-12®, HN019) matters for claims and dosing.
7. Safety Considerations and Regulatory Status
7.1 Regulatory Status
The species is listed in the Inventory of Microbial Food Cultures with Safety Demonstration in Fermented Food Products. The European Food Safety Authority (EFSA) has included the subspecies in the Qualified Presumption of Safety (QPS) list. In China, B. lactis HN019™ has been specifically permitted for use in infant and toddler (>1 year) food since 2011, and it was accepted to be Generally Recognized as Safe (GRAS, GRN445) in the US in 2012.
Bifidobacterium animalis subsp. lactis BB-12® in conventional foods has been determined to be Generally Recognized as Safe (GRAS) based on scientific procedures, as notified to the FDA. The FDA has stated it has no questions regarding the GRAS conclusion for certain strains, though such letters are not a formal affirmation of GRAS status under 21 CFR 170.35.
7.2 General Safety Profile
Publications supporting the safe consumption of B. animalis subsp. lactis include peer-reviewed scientific journals, governmental reviews, and product approvals. Published clinical trials in which infants, children, and adults were fed certain B. animalis strains noted that no significant adverse effects on participants were observed.
BB-12-supplemented yogurt was found to be safe and well tolerated when consumed by healthy adults concurrently taking antibiotics.
7.3 Antibiotic Resistance Genes
Genome analysis of multiple B. animalis subsp. lactis strains has identified antibiotic resistance genes conferring resistance to elfamycin, fluoroquinolones, macrolides, peptides, rifamycin, streptogramins, tetracyclines, aminocoumarins, fusidanes, and mupirocin-like compounds. Although the types of resistance genes were consistent among strains, the number of coding genes varied. The clinical relevance of these intrinsic genomic resistance elements in healthy individuals consuming commercially produced strains has not been established as a safety concern based on current regulatory assessments, but remains an active area of scientific monitoring.
7.4 Strain Non-Colonization and Transient Effects
Some probiotic forms derived from B. animalis may not colonize long-term, but still exert beneficial effects during supplementation. Overall, colonization depends on species, host factors, and dietary context. This means that any effects observed during a supplementation period may not persist after supplementation is discontinued, which is an important consideration when interpreting clinical outcomes.
7.5 Evidence Heterogeneity and Interpretation
The current evidence base is characterized by substantial strain heterogeneity, limited sample sizes, inconsistent intervention duration and dosing, and a focus on specific populations. Studies conducted so far have used different species, doses, and formulations, so their benefit remains controversial. This underscores that findings from one strain (e.g., BB-12®) cannot be automatically extrapolated to another strain within the same subspecies (e.g., HN019), and that clinical evidence must be evaluated on a strain-by-strain basis.
References
Go back